This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT03865953 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Lateral Pharma Pty Ltd |
| Enrollment | 53 participants |
| Design | Interventional, Randomized, Crossover, Masking: Quadruple |
| Conditions | Neuropathic Pain; Diabetic Peripheral Neuropathy (DPN); Post Herpetic Neuralgia (PHN) |
| Interventions | LAT8881; Placebo |
| Start | Apr 9, 2019 |
| Primary completion | Apr 19, 2020 |
| Study completion | May 3, 2020 |
| Results posted | Yes, in the registry |
| Registry last updated | Jun 14, 2021 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Absolute Change in Mean Pain Score, Using an 11 Point Numeric Pain Rating Scale (NPRS) | Baseline to Week 4 |
14 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
